Mi-Helper

Mi-Helper operates at the intersection of health care, medical devices, wellness, and clinical research. Its stated focus is an investigational, drug-free approach to migraine and mood issues, using transnasal airflow as a neuromodulation method. That gives the company a specific modality and use case, rather than a broad digital-health offering; the product is described as intended for potential use beyond clinical settings, including at home. The profile places Mi-Helper in a 11–50 employee band and records $8.714 million in funding across four entries, including a $4 million Series A in 2022 and two undisclosed rounds in 2025. These figures indicate a small company with a research-oriented medical technology program, but they do not establish commercial scale or clinical efficacy. Its differentiation should therefore be assessed against evidence of clinical outcomes, safety, usability, and progress toward market access, none of which is detailed here.

Mi-Helper was founded in 2021 and has recorded four funding milestones totaling $8.714 million. The first listed milestone is a $2 million National Institutes of Health grant dated Jan 1, 2022, followed by a $4 million Series A on Oct 10, 2022. The funding record then shows two undisclosed rounds in 2025: $2.24 million on Aug 25, 2025 and $474,000 on Sep 12, 2025. Its employee range is 11–50, but there is no hiring trend or growth rate available. Overall, the disclosed milestones suggest continued financing around development of a specialized migraine-focused device concept. The next meaningful indicators of trajectory would be concrete clinical evidence, regulatory progress, product availability, and whether the company can translate its transnasal-airflow approach into safe, effective use beyond research settings.